These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 16818513

  • 1. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
    Bhattacharyya RS, Krishnan AV, Swami S, Feldman D.
    Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
    [Abstract] [Full Text] [Related]

  • 2. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
    Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL.
    Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
    Cancer Res; 2009 Oct 15; 69(20):8141-9. PubMed ID: 19808968
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T.
    J Urol; 2000 Sep 15; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
    Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL.
    Carcinogenesis; 2005 Nov 15; 26(11):1896-904. PubMed ID: 15958518
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Arnold JT, Liu X, Allen JD, Le H, McFann KK, Blackman MR.
    Prostate; 2007 Aug 01; 67(11):1152-62. PubMed ID: 17503469
    [Abstract] [Full Text] [Related]

  • 11. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Aug 01; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 12. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE, Shin JS, Leem DG, Kim SD, Cho WJ, Lee KT.
    Chem Biol Interact; 2016 Dec 25; 260():196-207. PubMed ID: 27720946
    [Abstract] [Full Text] [Related]

  • 13. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    Hååg P, Bektic J, Bartsch G, Klocker H, Eder IE.
    J Steroid Biochem Mol Biol; 2005 Aug 25; 96(3-4):251-8. PubMed ID: 15982869
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH.
    Cancer Res; 2006 Oct 15; 66(20):10064-72. PubMed ID: 17047070
    [Abstract] [Full Text] [Related]

  • 15. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
    Yeap BB, Krueger RG, Leedman PJ.
    Endocrinology; 1999 Jul 15; 140(7):3282-91. PubMed ID: 10385425
    [Abstract] [Full Text] [Related]

  • 16. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP, Lin CY, Hsiao PH, Wang HD, Jiang SS, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.
    PLoS One; 2013 Jul 15; 8(12):e82625. PubMed ID: 24349321
    [Abstract] [Full Text] [Related]

  • 17. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A, Sallami S, Céraline J, Oueslati R.
    Cell Biol Int; 2013 May 15; 37(5):464-70. PubMed ID: 23418075
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 15; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 19. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 15; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 20. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
    Wang LG, Liu XM, Chiao JW.
    Carcinogenesis; 2006 Oct 15; 27(10):2124-32. PubMed ID: 16704988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.